Catalyst Calendar

Thu, Aug 13, 2026

1 updates

4:01 PM

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially

Trial Results • Phase 3Results event Thu, Aug 13, 2026alumis.com

Mon, Aug 10, 2026

1 updates

ALMS

4:05 PM

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long - term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q

Trial Results • Phase 3ONWARD3 topline results Mon, Aug 10, 2026alumis.com